These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16127070)

  • 1. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates.
    Petersen PJ; Bradford PA
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3910-8. PubMed ID: 16127070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method.
    Bradford PA; Petersen PJ; Young M; Jones CH; Tischler M; O'Connell J
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3903-9. PubMed ID: 16127069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of medium type, age and aeration on the MICs of tigecycline and classical tetracyclines.
    Hope R; Warner M; Mushtaq S; Ward ME; Parsons T; Livermore DM
    J Antimicrob Chemother; 2005 Dec; 56(6):1042-6. PubMed ID: 16286361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
    Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; López F; Alvarez J; Picazo JJ;
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):437-44. PubMed ID: 16949245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of tigecycline against multidrug-resistant Gram-negative blood culture isolates from critically ill patients.
    Gupta S; Aruna C; Nagaraj S; Dias M; Muralidharan S
    J Antimicrob Chemother; 2012 May; 67(5):1293-5. PubMed ID: 22258926
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.
    Bouchillon SK; Hoban DJ; Johnson BM; Stevens TM; Dowzicky MJ; Wu DH; Bradford PA
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):291-5. PubMed ID: 15808321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
    Sader HS; Jones RN; Stilwell MG; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):181-6. PubMed ID: 16105562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
    Roveta S; Marchese A; Debbia EA
    Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
    Bertrand X; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals.
    Souli M; Kontopidou FV; Koratzanis E; Antoniadou A; Giannitsioti E; Evangelopoulou P; Kannavaki S; Giamarellou H
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3166-9. PubMed ID: 16940120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.
    Rodloff AC; Leclercq R; Debbia EA; Cantón R; Oppenheim BA; Dowzicky MJ
    Clin Microbiol Infect; 2008 Apr; 14(4):307-14. PubMed ID: 18261126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of different Mueller-Hinton agars and media age on Etest susceptibility testing of tigecycline.
    Tan TY; Ng LS; Chen DM
    Diagn Microbiol Infect Dis; 2010 Sep; 68(1):93-5. PubMed ID: 20727479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of tigecycline and comparators against gram-negative bacteria isolated from a tertiary hospital in Alexandria, Egypt.
    Mohamed NM; Youssef AA
    Microb Drug Resist; 2011 Dec; 17(4):489-95. PubMed ID: 21875338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of tigecycline and comparators against organisms associated with intra-abdominal infections collected as part of TEST (2004-2009).
    Mayne D; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2012 Oct; 74(2):151-7. PubMed ID: 22770774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010.
    Hawser SP; Bouchillon SK; Hackel M; Chen M; Kim EC
    Int J Antimicrob Agents; 2012 Jun; 39(6):490-5. PubMed ID: 22534507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of tigecycline against clinical isolates from Shanghai, China.
    Zhang YY; Zhou L; Zhu DM; Wu PC; Hu FP; Wu WH; Wang F
    Diagn Microbiol Infect Dis; 2004 Dec; 50(4):267-81. PubMed ID: 15582300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.